Gritstone Bio Inc

NASDAQ:GRTS   3:59:56 PM EDT
4.72
-0.33 (-6.54%)
Products, Expansion

Gritstone bio and CEPI Expand Vaccine Agreement to Tackle Omicron Variant

Published: 12/06/2021 12:56 GMT
Gritstone Bio Inc (GRTS) - Gritstone Bio and Cepi Expand Vaccine Agreement to Tackle Omicron Variant.
Gritstone - Cepi Will Provide Up to $5 Million in Additional Funding to Conduct Phase 1 Clinical Trial of Co's Omicron Vaccine Candidate in South Africa.
Gritstone Bio - Commenced Manufacturing Sam Vaccine to Specifically Target Omicron Variant, Omicron Arms of Phase 1 Trial Expected to Begin in Q2 2022.